Solid lipid nanoparticles ofAnnona muricatafruit extract: formulation, optimization andin vitrocytotoxicity studies / Mohanalakshmi Sabapati, Narahari N. Palei, Ashok Kumar C.K., Ravindra Babu Molakpogu
Abstract The present study was aimed to develop Annona muricata fruit extract loaded solid lipid nanoparticles (SLNs) and explore its cytotoxic potential in vitro model of breast cancers. Extract loaded SLNs were successfully prepared by high-pressure homogenization followed by ultrasonication method and optimized using 2 3 full factorial design. The extract loaded SLNs were characterized using different parameters such as particle size (PS), % entrapment efficiency (EE), zeta potential (ZP) and % cumulative drug release (CDR). The SLNs formulation was optimized on the basis of software analysis with an overall desirability factor. The PS and %EE of the optimized formulation were found to be 134.8 nm and 83.26%, respectively. The optimized formulation showed a CDR of 79.83% up to 48 h. In vitro cytotoxicity efficacy of extract loaded SLNs was determined using MTT and Apoptosis assay and compared to that of a free extract. The SLNs showed a notable apoptotic effect and better efficacy to kill MCF7 cancer cells as compared to free extract. Thus, extract loaded SLNs could be an alternative dosage form which possibly controls therapeutic action with reducing side effect.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Drug development and industrial pharmacy - 45(2019), 4, Seite 577-586 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sabapati, Mohanalakshmi [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Annona muricata |
|---|
| Umfang: |
1 Online-Ressource (10 p) |
|---|
| doi: |
10.1080/03639045.2019.1569027 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011185694 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011185694 | ||
| 003 | DE-627 | ||
| 005 | 20230720210143.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230714s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/03639045.2019.1569027 |2 doi | |
| 035 | |a (DE-627)KFL011185694 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/03639045.2019.1569027 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Sabapati, Mohanalakshmi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Solid lipid nanoparticles ofAnnona muricatafruit extract: formulation, optimization andin vitrocytotoxicity studies |c Mohanalakshmi Sabapati, Narahari N. Palei, Ashok Kumar C.K., Ravindra Babu Molakpogu |
| 264 | 1 | |c 2019 | |
| 300 | |a 1 Online-Ressource (10 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract The present study was aimed to develop Annona muricata fruit extract loaded solid lipid nanoparticles (SLNs) and explore its cytotoxic potential in vitro model of breast cancers. Extract loaded SLNs were successfully prepared by high-pressure homogenization followed by ultrasonication method and optimized using 2 3 full factorial design. The extract loaded SLNs were characterized using different parameters such as particle size (PS), % entrapment efficiency (EE), zeta potential (ZP) and % cumulative drug release (CDR). The SLNs formulation was optimized on the basis of software analysis with an overall desirability factor. The PS and %EE of the optimized formulation were found to be 134.8 nm and 83.26%, respectively. The optimized formulation showed a CDR of 79.83% up to 48 h. In vitro cytotoxicity efficacy of extract loaded SLNs was determined using MTT and Apoptosis assay and compared to that of a free extract. The SLNs showed a notable apoptotic effect and better efficacy to kill MCF7 cancer cells as compared to free extract. Thus, extract loaded SLNs could be an alternative dosage form which possibly controls therapeutic action with reducing side effect | ||
| 653 | |a Annona muricata | ||
| 653 | |a SLNs | ||
| 653 | |a factorial design | ||
| 653 | |a cytotoxicity | ||
| 653 | |a MTT assay | ||
| 653 | |a apoptosis | ||
| 700 | 1 | |a Palei, Narahari N. |e verfasserin |4 aut | |
| 700 | 1 | |a C.K., Ashok Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Molakpogu, Ravindra Babu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug development and industrial pharmacy |d Abingdon : Taylor & Francis Group, 1977 |g 45(2019), 4, Seite 577-586 |h Online-Ressource |w (DE-627)KFL000005975 |w (DE-600)2008903-X |w (DE-576)116897511 |x 1520-5762 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2019 |g number:4 |g pages:577-586 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/03639045.2019.1569027 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_02 | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2019 |e 4 |h 577-586 | ||